We specifically targeted the most significantly mutated genes and regions in HCC (TERT promoter, TP53, CTNNB1, AXIN1 and ARID1A), evidencing that high-depth sequencing analysis of plasma-derived cfDNA could be used to detect tumor-related gene mutations in plasma cfDNA. This evidence concerns the gene TP53 and neoplasm.